341 results on '"Steubl, Dominik"'
Search Results
2. Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial
3. Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD
4. Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes
5. Association of serum uromodulin with mortality and cardiovascular disease in the elderly-the Cardiovascular Health Study.
6. Association of serum and urinary uromodulin and their correlates in older adults—The Cardiovascular Health Study
7. Efficacy and safety of avenciguat in diabetic and non-diabetic kidney disease: Pooled analysis from two Phase II randomised controlled clinical trials
8. Effect of Avenciguat on Albuminuria in Patients with CKD
9. Association of Serum Uromodulin With ESKD and Kidney Function Decline in the Elderly: The Cardiovascular Health Study
10. Urinary uromodulin independently predicts end-stage renal disease and rapid kidney function decline in a cohort of chronic kidney disease patients
11. A randomized prospective cross over study on the effects of medium cut-off membranes on T cellular and serologic immune phenotypes in hemodialysis
12. Serum Uromodulin: A Biomarker of Long-Term Kidney Allograft Failure
13. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced
14. Optimizing the Design and Analysis of Future AKI Trials
15. Genetic and Clinical Predictors of Age of ESKD in Individuals With Autosomal Dominant Tubulointerstitial Kidney Disease Due to UMOD Mutations
16. Treatment Effects Of Empagliflozin In Hospitalized Heart Failure Patients Across The Range Of Left Ventricular Ejection Fraction - Results From The EMPULSE Trial
17. Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD
18. Development and Validation of Residual Kidney Function Estimating Equations in Dialysis Patients
19. Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the EMPULSE trial.
20. Comparison of Peritoneal Low-Molecular-Weight-Protein-Removal in CCPD and CAPD Patients Based on C-Terminal Agrin Fragment Clearance.
21. Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk
22. Healthcare Costs Associated with the Development and Combination of Cardio-Renal-Metabolic Diseases
23. The Bidirectional Association of Chronic Kidney Disease, Type 2 Diabetes, Atherosclerotic Cardiovascular Disease, and Heart Failure: The Cardio–Renal–Metabolic Syndrome
24. Empagliflozin in Patients with Chronic Kidney Disease
25. Plasma C-terminal agrin fragment and rapid kidney function decline in chronic kidney disease patients
26. How best to estimate glomerular filtration rate? Novel filtration markers and their application
27. Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure
28. Influence of high-flux hemodialysis and hemodiafiltration on serum C-terminal agrin fragment levels in end-stage renal disease patients
29. Serum Uromodulin and All-Cause Mortality in Peritoneal Dialysis Patients: A Chinese Cohort Study
30. Clinical Validation of a Novel ELISpot-based in Vitro Diagnostic Assay to Monitor CMV-specific Cell-Mediated Immunity in Kidney Transplant Recipients
31. Hypothesis: Potential Utility of Serum and Urine Uromodulin Measurement in Kidney Transplant Recipients?
32. A novel citrate-based protocol versus heparin anticoagulation for sustained low-efficiency dialysis in the ICU: safety, efficacy, and cost
33. Genome-wide studies reveal factors associated with circulating uromodulin and its relationships to complex diseases
34. MO048: Genome-wide studies reveal factors associated with circulating uromodulin and its relations with complex diseases
35. Effects of empagliflozin on uric acid levels and gout: observations from the EMPA-REG OUTCOME trial
36. The Effect of Cardiometabolic Comorbidities on Risk of Chronic Kidney Disease Incidence: A Longitudinal Cohort Study
37. Genome-wide studies reveal factors associated with circulating uromodulin and its relationships to complex diseases
38. Comparison of a pocket-size ultrasound device with a premium ultrasound machine: diagnostic value and time required in bedside ultrasound examination
39. C-terminal agrin fragment (CAF) as a serum biomarker for residual renal function in peritoneal dialysis patients
40. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials
41. Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in more than 15 000 individuals
42. Cognitive impairment and microvascular function in end‐stage renal disease
43. Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction
44. Analysis of eGFR index category and annual eGFR slope association with adverse clinical outcomes using real-world Japanese data: a retrospective database study
45. Experimental and clinical nephroprotection by the xanthine oxidase inhibitor febuxostat
46. Early postoperative C-terminal agrin fragment (CAF) serum levels predict graft loss and proteinuria in renal transplant recipients
47. Assisted peritoneal dialysis across Europe: Practice variation and factors associated with availability
48. Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial
49. Barriers and opportunities to increase PD incidence and prevalence: Lessons from a European Survey
50. Estimating serum‐ionized magnesium concentration in hemodialysis patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.